Musculoskeletal manifestations in children with Behçet’s syndrome: data from the AIDA Network Behçet’s Syndrome Registry
dc.contributor.author | Gaggiano C. | |
dc.contributor.author | Maselli A. | |
dc.contributor.author | Sfikakis P.P. | |
dc.contributor.author | Laskari K. | |
dc.contributor.author | Ragab G. | |
dc.contributor.author | Hegazy M.T. | |
dc.contributor.author | Laymouna A.H. | |
dc.contributor.author | Lopalco G. | |
dc.contributor.author | Almaghlouth I.A. | |
dc.contributor.author | Asfina K.N. | |
dc.contributor.author | Alahmed O. | |
dc.contributor.author | Giardini Mayrink H.A. | |
dc.contributor.author | Parente de Brito Antonelli I. | |
dc.contributor.author | Cattalini M. | |
dc.contributor.author | Piga M. | |
dc.contributor.author | Sota J. | |
dc.contributor.author | Gentileschi S. | |
dc.contributor.author | Maggio M.C. | |
dc.contributor.author | Opris-Belinski D. | |
dc.contributor.author | Hatemi G. | |
dc.contributor.author | Insalaco A. | |
dc.contributor.author | Olivieri A.N. | |
dc.contributor.author | Tufan A. | |
dc.contributor.author | Karadeniz H. | |
dc.contributor.author | Kardaş R.C. | |
dc.contributor.author | La Torre F. | |
dc.contributor.author | Cardinale F. | |
dc.contributor.author | Marino A. | |
dc.contributor.author | Guerriero S. | |
dc.contributor.author | Ruscitti P. | |
dc.contributor.author | Tarsia M. | |
dc.contributor.author | Vitale A. | |
dc.contributor.author | Caggiano V. | |
dc.contributor.author | Telesca S. | |
dc.contributor.author | Iannone F. | |
dc.contributor.author | Parretti V. | |
dc.contributor.author | Frassi M. | |
dc.contributor.author | Aragona E. | |
dc.contributor.author | Ciccia F. | |
dc.contributor.author | Wiesik-Szewczyk E. | |
dc.contributor.author | Ionescu R. | |
dc.contributor.author | Şahin A. | |
dc.contributor.author | Akkoç N. | |
dc.contributor.author | Hinojosa-Azaola A. | |
dc.contributor.author | Tharwat S. | |
dc.contributor.author | Hernández-Rodríguez J. | |
dc.contributor.author | Espinosa G. | |
dc.contributor.author | Conti G. | |
dc.contributor.author | Del Giudice E. | |
dc.contributor.author | Govoni M. | |
dc.contributor.author | Emmi G. | |
dc.contributor.author | Fabiani C. | |
dc.contributor.author | Balistreri A. | |
dc.contributor.author | Frediani B. | |
dc.contributor.author | Rigante D. | |
dc.contributor.author | Cantarini L. | |
dc.date.accessioned | 2024-07-22T08:02:54Z | |
dc.date.available | 2024-07-22T08:02:54Z | |
dc.date.issued | 2023 | |
dc.description.abstract | This study aims to describe musculoskeletal manifestations (MSM) in children with Behçet’s syndrome (BS), their association with other disease manifestations, response to therapy, and long-term prognosis. Data were retrieved from the AIDA Network Behçet’s Syndrome Registry. Out of a total of 141 patients with juvenile BS, 37 had MSM at disease onset (26.2%). The median age at onset was 10.0 years (IQR 7.7). The median follow-up duration was 21.8 years (IQR 23.3). Recurrent oral (100%) and genital ulcers (67.6%) and pseudofolliculitis (56.8%) were the most common symptoms associated with MSM. At disease onset, 31 subjects had arthritis (83.8%), 33 arthralgia (89.2%), and 14 myalgia (37.8%). Arthritis was monoarticular in 9/31 cases (29%), oligoarticular in 10 (32.3%), polyarticular in 5 (16.1%), axial in 7 (22.6%). Over time, arthritis became chronic-recurrent in 67.7% of cases and 7/31 patients had joint erosions (22.6%). The median Behçet's Syndrome Overall Damage Index was 0 (range 0–4). Colchicine was inefficacious for MSM in 4/14 cases (28.6%), independently from the type of MSM (p = 0.46) or the concomitant therapy (p = 0.30 for cDMARDs, p = 1.00 for glucocorticoids); cDMARDs and bDMARDs were inefficacious for MSM in 6/19 (31.4%) and 5/12 (41.7%) cases. The presence of myalgia was associated with bDMARDs inefficacy (p = 0.014). To conclude, MSM in children with BS are frequently associated with recurrent ulcers and pseudofolliculitis. Arthritis is mostly mono- or oligoarticular, but sacroiliitis is not unusual. Prognosis of this subset of BS is overall favorable, though the presence of myalgia negatively affects response to biologic therapies. ClinicalTrials.gov Identifier: NCT05200715 (registered on December 18, 2021). © 2023, The Author(s). | |
dc.identifier.DOI-ID | 10.1007/s11739-023-03215-w | |
dc.identifier.issn | 18280447 | |
dc.identifier.uri | http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12048 | |
dc.language.iso | English | |
dc.publisher | Springer Science and Business Media Deutschland GmbH | |
dc.rights | All Open Access; Hybrid Gold Open Access | |
dc.subject | Arthritis | |
dc.subject | Behcet Syndrome | |
dc.subject | Child | |
dc.subject | Humans | |
dc.subject | Myalgia | |
dc.subject | Registries | |
dc.subject | Ulcer | |
dc.subject | arthritis | |
dc.subject | Behcet disease | |
dc.subject | child | |
dc.subject | complication | |
dc.subject | human | |
dc.subject | myalgia | |
dc.subject | register | |
dc.subject | ulcer | |
dc.title | Musculoskeletal manifestations in children with Behçet’s syndrome: data from the AIDA Network Behçet’s Syndrome Registry | |
dc.type | Article |